Home

Chimeric Therapeutics (ASX:CHM) Expands Cancer Trials

PUBLISHED

2022-05-18

Content



Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow provides an update on clinical trial progression, and discusses recent agreements with WuXi Advanced Therapies and Be The Match BioTherapies.